Evidence map›Paper›PMID 42051022›Full record

ArticleActa dermato-venereologica2026

Epidemiology and Comorbidity of Vitiligo in Germany: A Claims Data Analysis.

Theresa Klinger, Matthias Augustin, Susanne Baumeister, Jennifer Riedel, Claudia Grellmann, Anja Kamps, Markus Böhm, Kristina Hagenström

Abstract read
In one paragraph

Article in Acta dermato-venereologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Theresa KlingerInstitute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany. t.klinger@uke.de.ORCID 0009-0003-0760-3103
Matthias AugustinInstitute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.ORCID 0000-0002-4026-8728
Susanne BaumeisterIncyte Biosciences Germany, Munich, Germany.
Jennifer RiedelGesundheitsforen Leipzig GmbH, Leipzig, Germany.
Claudia Grellmanninav - Private Institute for Applied Health Services Research GmbH, Berlin, Germany.
Anja KampsIncyte Biosciences Germany, Munich, Germany.
Markus BöhmDepartment of Dermatology, University of Münster, Münster, Germany.ORCID 0000-0001-7338-7734
Kristina HagenströmInstitute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.ORCID 0000-0002-2676-1479

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vitiligo is a chronic skin disease resulting in destruction of melanocytes and loss of pigmentation. Little is known about epidemiology and comorbidity in Germany. This retrospective cohort analysis used nationwide statutory health insurance data (2016 to 2020). Disease rates were calculated using varying case definitions. Comorbidity was assessed against 3 control groups: persons without vitiligo, with atopic dermatitis, and with psoriasis (1:3 propensity score matching). In 2020, 4,631 persons were diagnosed with vitiligo in DAK-Gesundheit (DAK-G, mean age 56.93 years, ~148,437) and 5,820 persons in the German Analysis Database for Evaluation and Health Services Research (~144,855). Prevalence ranged from 0.12% (confidence interval [CI] 0.12-0.12) to 0.20% (CI 0.19-0.20), and incidence from 0.04% (CI 0.03-0.04) to 0.06% (CI 0.06-0.06). Rates increased with age. Women (mean age 58.60 years) were more frequently affected. Vitiligo was associated with alopecia areata (relative risk 7.14, CI 4.63-11.00) and systemic sclerosis (relative risk 3.20, CI 1.58-6.47). Several mental illnesses (depression: relative risk = 1.23, CI 1.15-1.32, anxiety: relative risk = 1.32, CI 1.19-1.47), were linked to skin diseases like vitiligo, atopic dermatitis, or psoriasis. Vitiligo affects a notable proportion of the population, with detected comorbidities supporting prior findings. To ensure reliable results, claims data should be validated through primary data linkage or sensitivity testing.

Indexed as

VitiligoAdolescentAdultAgedAged, 80 and overAge DistributionAlopecia AreataChildChild, PreschoolComorbidityDatabases, FactualDermatitis, AtopicFemaleGermanyHumansIncidence

Identifiers

PMID42051022
PMCPMC13136925

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.